Classic reaction kinetics can explain complex patterns of antibiotic action

Science Translational Medicine

Volumn 7, Issue 287, 2015, Pages

  Abel Zur Wiesch, Pia ^a,b   Abel, Sören ^a,c   Gkotzis, Spyridon ^d   Ocampo, Paolo ^e,f   Engelstädter, Jan ^g   Hinkley, Trevor ^h   Magnus, Carsten ⁱ   Waldor, Matthew K ^a,j   Udekwu, Klas ^d   Cohen, Ted ^a,b,k  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b YALE UNIVERSITY   (United States)

^c UNIVERSITY OF TROMSØ   (Norway)

^d KAROLINSKA INSTITUTE   (Sweden)

^e ETH ZURICH   (Switzerland)

^f SWISS FEDERAL INSTITUTE OF AQUATIC SCIENCE AND TECHNOLOGY   (Switzerland)

^g UNIVERSITY OF QUEENSLAND   (Australia)

^h UNIVERSITY OF GLASGOW   (United Kingdom)

ⁱ UNIVERSITY OF ZURICH   (Switzerland)

^j HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^k HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL GROWTH; BACTERICIDAL ACTIVITY; BINDING KINETICS; CELL TRANSFORMATION; CHEMICAL BINDING; CHEMICAL REACTION KINETICS; CONCENTRATION RESPONSE; CONTROLLED STUDY; ESCHERICHIA COLI; GROWTH INHIBITION; MATHEMATICAL MODEL; MICROBIAL POPULATION DYNAMICS; NONHUMAN; PRIORITY JOURNAL; THEORETICAL MODEL; TUBERCULOSIS; VIBRIO CHOLERAE; DRUG EFFECTS; KINETICS; MICROBIAL SENSITIVITY TEST;

ANTIINFECTIVE AGENT;

ANTI-BACTERIAL AGENTS; ESCHERICHIA COLI; KINETICS; MICROBIAL SENSITIVITY TESTS; VIBRIO CHOLERAE;

EID: 84929648835     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.aaa8760     Document Type: Article

References (82)

1. K. E. Dooley, C. D. Mitnick, M. A. De Groote, E. Obuku, V. Belitsky, C. D. Hamilton, M. Makhene, S. Shah, J. C M. Brust, N. Durakovic, E. Nuermberger, Old drugs, new purpose: Retooling existing drugs for optimized treatment of resistant tuberculosis. Clin. Infect. Dis. 55, 572-581 (2012).
2. G. L. Drusano, Antimicrobial pharmacodynamics: Critical interactions of "bug and drug". Nat. Rev. Microbiol. 2, 289-300 (2004).
3. K. S. Ingersoll, J. Cohen, The impact of medication regimen factors on adherence to chronic treatment: A review of literature. J. Behav. Med. 31, 213-224 (2008).
4. D. Menzies, A. Benedetti, A. Paydar, I. Martin, S. Royce, M. Pai, A. Vernon, C. Lienhardt, W. Burman, Effect of duration and intermittency of rifampin on tuberculosis treatment outcomes: A systematic review and meta-analysis. PLOS Med. 6, e1000146 (2009).
5. K. C. Chang, C. C. Leung, J. Grosset, W. W. Yew, Treatment of tuberculosis and optimal dosing schedules. Thorax 66, 997-1007 (2011).
6. A. Bose, S. Kalita, W. Rose, P. Tharyan, Intermittent versus daily therapy for treating tuberculosis in children. Cochrane Database Syst. Rev. 1, CD007953 (2014).
7. E. Gelman, J. D. McKinney, N. Dhar, Malachite green interferes with postantibiotic recovery of mycobacteria. Antimicrob. Agents Chemother. 56, 3610-3614 (2012).
8. I. Odenholt-Tornqvist, Studies on the postantibiotic effect and the postantibiotic sub-MIC effect of meropenem. J. Antimicrob. Chemother. 31, 881-892 (1993).
9. A. Zumla, P. Nahid, S. T. Cole, Advances in the development of new tuberculosis drugs and treatment regimens. Nat. Rev. Drug Discov. 12, 388-404 (2013).
10. J. A. Roberts, S. K. Paul, M. Akova, M. Bassetti, J. J. De Waele, G. Dimopoulos, K. M. Kaukonen, D. Koulenti, C. Martin, P. Montravers, DALI: Defining antibiotic levels in intensive care unit patients: Are current β-lactam antibiotic doses sufficient for critically ill patients? Clin. Infect. Dis. 58, 1072-1083 (2014).
11. K. I. Udekwu, N. Parrish, P. Ankomah, F. Baquero, B. R. Levin, Functional relationship between bacterial cell density and the efficacy of antibiotics. J. Antimicrob. Chemother. 63, 745-757 (2009).
12. J. M. Yarwood, D. J. Bartels, E. M. Volper, E. P. Greenberg, Quorum sensing in Staphylococcus aureus biofilms. J. Bacteriol. 186, 1838-1850 (2004).
13. L. D. Sabath, C. Garner, C. Wilcox, M. Finland, Effect of inoculum and of beta-lactamase on the anti-staphylococcal activity of thirteen penicillins and cephalosporins. Antimicrob. Agents Chemother. 8, 344-349 (1975).
14. D. L. Stevens, S. Yan, A. E. Bryant, Penicillin-binding protein expression at different growth stages determines penicillin efficacy in vitro and in vivo: An explanation for the inoculum effect. J. Infect. Dis. 167, 1401-1405 (1993).
15. P. A. Zur Wiesch, R. Kouyos, J. Engelstädter, R. R. Regoes, S. Bonhoeffer, Population biological principles of drug-resistance evolution in infectious diseases. Lancet Infect. Dis. 11, 236-247 (2011).
16. Performance Standards for Antimicrobial Susceptibility Testing (Clinical and Laboratory Standards Institute, Wayne, PA, 2005).
17. Y. H. Lee, G. Liu, D. M. Thiboutot, D. L. Leslie, J. S. Kirby, A retrospective analysis of the duration of oral antibiotic therapy for the treatment of acne among adolescents: Investigating practice gaps and potential cost-savings. J. Am. Acad. Dermatol. 71, 70-76 (2014).
18. D. R. Cranendonk, B. C. Opmeer, J. M. Prins, W. J. Wiersinga, Comparing short to standard duration of antibiotic therapy for patients hospitalized with cellulitis (DANCE): Study protocol for a randomized controlled trial. BMC Infect. Dis. 14, 235 (2014).
19. A. Hohn, S. Schroeder, A. Gehrt, K. Bernhardt, B. Bein, K. Wegscheider, M. Hochreiter, Procalcitoninguided algorithm to reduce length of antibiotic therapy in patients with severe sepsis and septic shock. BMC Infect. Dis. 13, 158 (2013).
20. A. I. Zumla, S. H. Gillespie, M. Hoelscher, P. P. J. Philips, S. T. Cole, I. Abubakar, T. D. McHugh, M. Schito, M. Maeurer, A. J. Nunn, New antituberculosis drugs, regimens, and adjunct therapies: Needs, advances, and future prospects. Lancet Infect. Dis. 14, 327-340 (2014).
21. G. Dimopoulos, G. Poulakou, I. A. Pneumatikos, A. Armaganidis, M. H. Kollef, D. K. Matthaiou, Short-vs long-duration antibiotic regimens for ventilator-associated pneumonia: A systematic review and meta-analysis. Chest 144, 1759-1767 (2013).
22. D. Guillemot, C. Carbon, B. Balkau, P. Geslin, H. Lecoeur, F. Vauzelle-Kervroëdan, G. Bouvenot, E. Eschwége, Low dosage and long treatment duration of β-lactam: Risk factors for carriage of penicillin-resistant Streptococcus pneumoniae. JAMA 279, 365-370 (1998).
23. N. Q. Balaban, J. Merrin, R. Chait, L. Kowalik, S. Leibler, Bacterial persistence as a phenotypic switch. Science 305, 1622-1625 (2004).
24. N. Q. Balaban, K. Gerdes, K. Lewis, J. D. McKinney, A problem of persistence: Still more questions than answers? Nat. Rev. Microbiol. 11, 587-591 (2013).
25. N. R. Cohen, M. A. Lobritz, J. J. Collins, Microbial persistence and the road to drug resistance. Cell Host Microbe 13, 632-642 (2013).
26. T. Dörr, K. Lewis, M. Vulic, SOS response induces persistence to fluoroquinolones in Escherichia coli. PLOS Genet. 5, e1000760 (2009).
27. J. Feng, D. A. Kessler, E. Ben-Jacob, H. Levine, Growth feedback as a basis for persister bistability. Proc. Natl. Acad. Sci. U. S. A. 111, 544-549 (2014).
28. S. S. Grant, B. B. Kaufmann, N. S. Chand, N. Haseley, D. T. Hung, Eradication of bacterial persisters with antibiotic-generated hydroxyl radicals. Proc. Natl. Acad. Sci. U. S. A. 109, 12147-12152 (2012).
29. P. J. T. Johnson, B. R. Levin, Pharmacodynamics, population dynamics, and the evolution of persistence in Staphylococcus aureus. PLOS Genet. 9, e1003123 (2013).
30. G. R. Stewart, B. D. Robertson, D. B. Young, Tuberculosis: A problem with persistence. Nat. Rev. Microbiol. 1, 97-105 (2003).
31. Y. Wakamoto, N. Dhar, R. Chait, K. Schneider, F. Signorino-Gelo, S. Leibler, J. D. McKinney, Dynamic persistence of antibiotic-stressed mycobacteria. Science 339, 91-95 (2013).
32. T. Dörr, M. Vulic, K. Lewis, Ciprofloxacin causes persister formation by inducing the TisB toxin in Escherichia coli. PLOS Biol. 8, e1000317 (2010).
33. K. Lewis, Persister cells, dormancy and infectious disease. Nat. Rev. Microbiol. 5, 48-56 (2007).
34. O. Fridman, A. Goldberg, I. Ronin, N. Shoresh, N. Q. Balaban, Optimization of lag time underlies antibiotic tolerance in evolved bacterial populations. Nature 513, 418-421 (2014).
35. J. L. Martínez, F. Baquero, D. I. Andersson, Predicting antibiotic resistance. Nat. Rev. Microbiol. 5, 958-965 (2007).
36. P. S. Ocampo, V. Lázár, B. Papp, M. Arnoldini, P. Abel Zur Wiesch, R. Busa-Fekete, G. Fekete, C. Pál, M. Ackermann, S. Bonhoeffer, Antagonism between bacteriostatic and bactericidal antibiotics is prevalent. Antimicrob. Agents Chemother. 58, 4573-4582 (2014).
37. M. Scott, C. W. Gunderson, E. M. Mateescu, Z. Zhang, T. Hwa, Interdependence of cell growth and gene expression: Origins and consequences. Science 330, 1099-1102 (2010).
38. S. Gudmundsson, S. Einarsson, H. Erlendsdottir, J. Moffat, W. Bayer, W. A. Craig, The postantibiotic effect of antimicrobial combinations in a neutropenic murine thigh infection model. J. Antimicrob. Chemother. 31(Suppl. D), 177-191 (1993).
39. M. G. Täuber, O. Zak, W. M. Scheld, B. Hengstler, M. A. Sande, The postantibiotic effect in the treatment of experimental meningitis caused by Streptococcus pneumoniae in rabbits. J. Infect. Dis. 149, 575-583 (1984).
40. W. A. Craig, Post-antibiotic effects in experimental infection models: Relationship to in-vitro phenomena and to treatment of infections in man. J. Antimicrob. Chemother. 31(Suppl. D), 149-158 (1993).
41. R. R. Regoes, C. Wiuff, R. M. Zappala, K. N. Garner, F. Baquero, B. R. Levin, Pharmacodynamic functions: A multiparameter approach to the design of antibiotic treatment regimens. Antimicrob. Agents Chemother. 48, 3670-3676 (2004).
42. S. Bakshi, A. Siryaporn, M. Goulian, J. C. Weisshaar, Superresolution imaging of ribosomes and RNA polymerase in live Escherichia coli cells. Mol. Microbiol. 85, 21-38 (2012).
43. L. Molinengo, The curve doses vs survival time in the evaluation of acute toxicity. J. Pharm. Pharmacol. 31, 343-344 (1979).
44. S. Magnet, J. S. Blanchard, Molecular insights into aminoglycoside action and resistance. Chem. Rev. 105, 477-498 (2005).
45. R. Williamson, R. Hakenbeck, A. Tomasz, In vivo interaction of beta-lactam antibiotics with the penicillin-binding proteins of Streptococcus pneumoniae. Antimicrob. Agents Chemother. 18, 629-637 (1980).
46. H. F. Chambers, M. J. Sachdeva, C. J. Hackbarth, Kinetics of penicillin binding to penicillinbinding proteins of Staphylococcus aureus. Biochem. J. 301(Pt. 1), 139-144 (1994).
47. T. J. Dougherty, K. Kennedy, R. E. Kessler, M. J. Pucci, Direct quantitation of the number of individual penicillin-binding proteins per cell in Escherichia coli. J. Bacteriol. 178, 6110-6115 (1996).
48. R. C. Li, Simultaneous pharmacodynamic analysis of the lag and bactericidal phases exhibited by beta-lactams against Escherichia coli. Antimicrob. Agents Chemother. 40, 2306-2310 (1996).
49. N. E. Freed, O. K. Silander, B. Stecher, A. Böhm, W. D. Hardt, M. Ackermann, A simple screen to identify promoters conferring high levels of phenotypic noise. PLOS Genet. 4, e1000307 (2008).
50. O. K. Silander, N. Nikolic, A. Zaslaver, A. Bren, I. Kikoin, U. Alon, M. Ackermann, A genomewide analysis of promoter-mediated phenotypic noise in Escherichia coli. PLOS Genet. 8, e1002443 (2012).
51. A. Jindani, C. J. Doré, D. A. Mitchison, Bactericidal and sterilizing activities of antituberculosis drugs during the first 14 days. Am. J. Respir. Crit. Care Med. 167, 1348-1354 (2003).
52. H. M. Ziglam, Rifampicin concentrations in bronchial mucosa, epithelial lining fluid, alveolar macrophages and serum following a single 600 mg oral dose in patients undergoing fibre-optic bronchoscopy. J. Antimicrob. Chemother. 50, 1011-1015 (2002).
53. J. J. Wilkins, R. M. Savic, M. O. Karlsson, G. Langdon, H. McIlleron, G. Pillai, P. J. Smith, U. S. Simonsson, Population pharmacokinetics of rifampin in pulmonary tuberculosis patients, including a semimechanistic model to describe variable absorption. Antimicrob. Agents Chemother. 52, 2138-2148 (2008).
54. D. Shah, Z. Zhang, A. Khodursky, N. Kaldalu, K. Kurg, K. Lewis, Persisters: A distinct physiological state of E. coli. BMC Microbiol. 6, 53 (2006).
55. E. Maisonneuve, K. Gerdes, Molecular mechanisms underlying bacterial persisters. Cell 157, 539-548 (2014).
56. B. Javid, F. Sorrentino, M. Toosky, W. Zheng, J. T. Pinkham, N. Jain, M. Pan, F. Deighan, E. J. Rubin, Mycobacterial mistranslation is necessary and sufficient for rifampicin phenotypic resistance. Proc. Natl. Acad. Sci. U. S. A. 111, 1132-1137 (2014).
57. G. Manina, N. Dhar, J. D. McKinney, Stress and host immunity amplify Mycobacterium tuberculosis phenotypic heterogeneity and induce nongrowing metabolically active forms. Cell Host Microbe 17, 32-46 (2015).
58. S. L. Spencer, S. Gaudet, J. G. Albeck, J. M. Burke, P. K. Sorger, Non-genetic origins of cell-to-cell variability in TRAIL-induced apoptosis. Nature 459, 428-432 (2009).
59. B. R. Levin, D. E. Rozen, Non-inherited antibiotic resistance. Nat. Rev. Microbiol. 4, 556-562 (2006).
60. J. K. Patel, C. B. Read, Handbook of the Normal Distribution (Taylor & Francis, London, ed. 2, 1996).
61. D. J. C. MacKay, Information Theory, Inference and Learning Algorithms (Cambridge Univ. Press, Cambridge, 2003).
62. S. Chanwong, N. Maneekarn, L. Makonkawkeyoon, S. Makonkawkeyoon, Intracellular growth and drug susceptibility of Mycobacterium tuberculosis in macrophages. Tuberculosis 87, 130-133 (2007).
63. B. Wiseman, X. Carpena, M. Feliz, L. J. Donald, M. Pons, I. Fita, P. C. Loewen, Isonicotinic acid hydrazide conversion to isonicotinyl-NAD by catalase-peroxidases. J. Biol. Chem. 285, 26662-26673 (2010).
64. M. Nilsson, L. Bülow, K. G. Wahlund, Use of flow field-flow fractionation for the rapid quantitation of ribosome and ribosomal subunits in Escherichia coli at different protein production conditions. Biotechnol. Bioeng. 54, 461-467 (1997).
65. H. Bremer, P. P. Dennis, in In Escherichia coli and Salmonella typhimurium: Cellular and Molecular Biology, F. C. Neidhardt, Ed. (American Society for Microbiology, Washington, DC, 1987), pp. 1553-1569.
66. B. Epe, P. Woolley, The binding of 6-demethylchlortetracycline to 70S, 50S and 30S ribosomal particles: A quantitative study by fluorescence anisotropy. EMBO J. 3, 121-126 (1984).
67. B. Zakeri, G. D. Wright, Chemical biology of tetracycline antibiotics. Biochem. Cell Biol. 86, 124-136 (2008).
68. M. Pioletti, F. Schlünzen, J. Harms, R. Zarivach, M. Glühmann, H. Avila, A. Bashan, H. Bartels, T. Auerbach, C. Jacobi, T. Hartsch, A. Yonath, F. Franceschi, Crystal structures of complexes of the small ribosomal subunit with tetracycline, edeine and IF3. EMBO J. 20, 1829-1839 (2001).
69. T. R. Tritton, Ribosome-tetracycline interactions. Biochemistry 16, 4133-4138 (1977).
70. F. Tangy, M. Moukkadem, E. Vindimian, M. L. Capmau, F. Le Goffic, Mechanism of action of gentamicin components. Characteristics of their binding to Escherichia coli ribosomes. Eur. J. Biochem. 147, 381-386 (1985).
71. B. Llano-Sotelo, R. P. Hickerson, L. Lancaster, H. F. Noller, A. S. Mankin, Fluorescently labeled ribosomes as a tool for analyzing antibiotic binding. RNA 15, 1597-1604 (2009).
72. F. N. Chang, J. G. Flaks, Binding of dihydrostreptomycin to Escherichia coli ribosomes: Kinetics of the reaction. Antimicrob. Agents Chemother. 2, 308-319 (1972).
73. D. Lando, M. A. Cousin, T. Ojasoo, J. P. Raymond, Paromomycin and dihydrostreptomycin binding to Escherichia coli ribosomes. Eur. J. Biochem. 66, 597-606 (1976).
74. B. G. Spratt, Distinct penicillin binding proteins involved in the division, elongation, and shape of Escherichia coli K12. Proc. Natl. Acad. Sci. U. S. A. 72, 2999-3003 (1975).
75. M. Terrak, T. K. Ghosh, J. Van Heijenoort, J. Van Beeumen, M. Lampilas, J. Aszodi, J. A. Ayala, J. M. Ghuysen, M. Nguyen-Distèche, The catalytic, glycosyl transferase and acyl transferase modules of the cell wall peptidoglycan-polymerizing penicillin-binding protein 1b of Escherichia coli. Mol. Microbiol. 34, 350-364 (1999).
76. T. Maier, A. Schmidt, M. Güell, S. Kühner, A. C. Gavin, R. Aebersold, L. Serrano, Quantification of mRNA and protein and integration with protein turnover in a bacterium. Mol. Syst. Biol. 7, 511 (2011).
77. J. Malmström, M. Beck, A. Schmidt, V. Lange, E. W. Deutsch, R. Aebersold, Proteome-wide cellular protein concentrations of the human pathogen Leptospira interrogans. Nature 460, 762-765 (2009).
78. W. Wehrli, Kinetic studies of the interaction between rifampicin and DNA-dependent RNA polymerase of Escherichia coli. Eur. J. Biochem. 80, 325-330 (1977).
79. B. D. Bennett, E. H. Kimball, M. Gao, R. Osterhout, S. J. Van Dien, J. D. Rabinowitz, Absolute metabolite concentrations and implied enzyme active site occupancy in Escherichia coli. Nat. Chem. Biol. 5, 593-599 (2009).
80. Y. Taniguchi, P. J. Choi, G. W. Li, H. Chen, M. Babu, J. Hearn, A. Emili, X. S. Xie, Quantifying E.coli proteome and transcriptome with single-molecule sensitivity in single cells. Science 329, 533-538 (2010).
81. M. Wilming, K. Johnsson, Spontaneous formation of the bioactive form of the tuberculosis drug isoniazid. Angew. Chem. Int. Ed. Engl. 38, 2588-2590 (1999).
82. R. Rawat, A. Whitty, P. J. Tonge, The isoniazid-NAD adduct is a slow, tight-binding inhibitor of InhA, the Mycobacterium tuberculosis enoyl reductase: Adduct affinity and drug resistance. Proc. Natl. Acad. Sci. U. S. A. 100, 13881-13886 (2003).